The significance of Hypertriglyceridemia in life-style diseases

Not Applicable

Recruiting

• Conditions: Metabolic syndrome, obesity, diabetes, hypertension, chronic kidney disease (CKD)

• Registration Number: JPRN-UMIN000037710
• Lead Sponsor: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-08-17
• Last Update Posted: 17 October 2023
• Study Completion: 2026-03-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

The patients who are judged as inappropriate for the study and who disagree the enrollment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Diagnosis and classification of dyslipidemia. 2. Identification of mutations for the known responsible genes for the development of dyslipidemia such as LPL. APOC2, APOC3, APOA5, LMF1, GPIHBP1, GCKR, CREB3L3, GPD1. (Since the current study is cross-sectional clinical study, there is no observation period.)

Secondary Outcome Measures

Name	Time	Method
1. Measurement of HMGB1, HRG, mir-221/222, mir-335, mir-342 in serum and plasma samples. 2. Identification of unknown causal genes for development of dyslipidemia.